SAMD12 and cancer: We reviewed the literature of these lncRNAs researched in tumors, and found that SAMD12-AS1 could promote gastric cancer progression via DNMT1/P53 axis [24], down-regulate P53 to promote malignant progression of glioma [25], and regulate hepatocellular carcinoma proliferation and apoptosis via the NPM1-HDM2-p53 axis [26], which indicated SAMD12-AS1 could be envisioned as a novel biomarker and therapeutic target for those cancers.